ArticleFrontiers in oncology2026
Clinicopathological characteristics and prognosis of early-onset colorectal cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical and pathological characteristics of patients with early-onset colorectal cancer (EOCRC) and to evaluate their impact on postoperative overall survival (OS) within the observed follow-up period. Methods: Consecutive colorectal cancer patients who underwent radical surgery at Zhangzhou Affiliated Hospital of Fujian Medical University between 2017 and 2024 were included. Patients were categorised into EOCRC group (≤50 years), and late-onset colorectal cancer (LOCRC) group (>50 years) based on age at diagnosis. To reduce baseline confounding, 1:4 propensity score matching (PSM) was performed. Stratified survival analyses were conducted across different TNM staging levels. Results: A total of 4,596 colorectal cancer patients were included, including 590 cases of EOCRC and 4,006 cases of LOCRC. Prior to PSM, EOCRC patients showed a higher proportion of females, lower ASA staging, increased prevalence of poorly differentiated tumours, mucinous adenocarcinoma/signet ring cell carcinoma, and dMMR status, alongside a relatively more advanced stage distribution. Median follow-up duration was 34.5 months. Both in the unmatched and matched cohorts, EOCRC patients demonstrated significantly superior OS compared to LOCRC patients. Multivariate Cox regression analysis demonstrated that EOCRC was an independent protective factor for OS both before (HR = 0.650, 95% CI 0.520-0.814) and after matching (HR = 0.641, 95% CI 0.509-0.809). Further stratified analysis by disease stage indicated that, among patients with stages I-IV disease, EOCRC demonstrated non-inferior OS outcomes compared with LOCRC, with the survival advantage being more pronounced in stage II and stage III patients. Conclusion: In a large single-centre retrospective cohort, despite presenting with certain unfavourable clinical and pathological characteristics at diagnosis, patients with EOCRC demonstrated OS comparable to those with LOCRC, exhibiting superior survival trends in certain staging groups. Prognosis assessment and clinical management of colorectal cancer should not rely solely on age at onset, but rather involve comprehensive decision-making incorporating staging, pathological features, and the patient's overall condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.